MDMehak Dangi

Mehak Dangi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mehak Dangi has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Computational Discovery of Phytochemicals Targeting InhA of Mycobacterium tuberculosis: Insights from Molecular Docking, MMGBSA, ADME Profiling, and Molecular Dynamics Simulations

    by Dev Kumar, Bhoomika, Alka Khichi, Ritu Jakhar, Mehak Dangi

    Introduction: Tuberculosis (TB) is one of the most serious global health issues, with the increasing number of multidrug-resistant TB cases emphasizing the need for new therapeutic approaches. Phytochemicals, with their diverse structures and favorable safety profiles, are a largely unexplored area for anti-TB drug development. Methods: An ethnobotanical study and literature analysis identified 310 medicinal plants traditionally used to treat respiratory infections, which produced 4,087 phytochemicals. Their structures were obtained from PubChem or drawn using ChemDraw, and pharmacokinetic properties were analyzed using QikProp. Enoyl-acyl carrier protein reductase (InhA, PDB ID: 4TRO), an important enzyme involved in mycolic acid biosynthesis, was selected as the target protein. Molecular docking was performed using Glide, followed by MMGBSA calculations, and the best hits were validated by 300 ns molecular dynamics simulations using the GROMACS pipeline. Results: Binding affinities showed that four phytochemicals, namely Patuletin, skimmin, flavonol- 3-O-D-glycoside, and salicin, had significantly higher binding affinity scores (-10.06 to -8.82 kcal/mol) than first-line anti-TB drugs isoniazid (-6.35 kcal/mol) and pyrazinamide (-4.22 kcal/mol). Patuletin and skimmin had MM-GBSA binding affinity scores of -74.89 and -71.76 kcal/mol, respectively. MD simulations of the top 3 compounds and control showed that the protein-ligand complexes were stable, as indicated by the RMSD, RMSF, Radius of gyration, SASA, and HBONDS. Discussion: Patuletin and Skimmin demonstrated strong binding affinity and structural stability against the InhA enzyme (PDB: 4TRO), indicating their potential as promising lead compounds for anti-tuberculosis effects. Derived from ethnomedicinal plants, these phytochemicals not only target key mycobacterial pathways but may also offer hepatoprotective and immunomodulatory benefits. The findings support the exploration of plant-derived compounds as safer and effective alternatives or adjuncts to conventional anti-TB therapies. Conclusion: The combination of virtual screening, ADME studies, and MD simulations enabled the identification of phytochemicals with promising interactions toward InhA, an established anti-TB target. The findings are based solely on computational analysis and should be interpreted as preliminary evidence of target engagement rather than confirmed inhibitory activity or therapeutic efficacy. These natural products may serve as potential lead compounds for further anti-tubercular drug discovery, warranting subsequent biochemical, cellular, and in vivo validation to establish their inhibitory potential, safety, and pharmacological effectiveness.

  • Open Access

    Combating Streptococcus agalactiae infections by designing a multi-epitope vaccine using molecular dynamic simulations

    by Jasmine Arya, Deepshikha Kaushik, Bhawna Berwal, Awadhesh Kumar, Rakesh Kumar, Shivani Budhwar, Navita Chaudhary, Himanshi Dahiya, Kirti Nain, Astha Chhillar, et al.

  • Open Access

    NUAK2 Pathogenic Variants Are Definitively Associated with Neural Tube Defects in Humans: New Genotype-Phenotype Correlation and Review of the Literature

    by Gioia Mastromoro, Claudio Dello Russo, Stefania Mariani, Serena Bucossi, Riccardo Riccardi, Amit Pal, Rosanna Squitti, Mehak Dangi, Antonio Pizzuti, Mauro Ciro Antonio Rongioletti

    Background and Clinical Significance: Neural tube defects (NTDs) represent a group of malformations, typically arising from a complex interplay between genetic susceptibility and environmental influences. Increasing evidence points to the contribution of rare pathogenic variants in genes involved in embryonic development in selected cases. To date, two families with NTDs carrying biallelic variants in TRIM36 and NUAK2 have been described. Specifically, germline homozygous pathogenic variants in NUAK2 were identified in three fetuses with anencephaly, thus implicating this gene as a critical regulator of neural tube closure. Case Presentation: We describe a family in which five individuals presented with sacral dimples, a subtle midline defect considered a minor malformation. Exome sequencing revealed a heterozygous missense variant, c.487G>A in NUAK2, segregating with the phenotype. Although sacral dimples are often clinically silent and do not typically cause functional impairment, their presence in multiple relatives highlights a possible shared genetic etiology. Careful phenotypic recognition of such findings can therefore provide valuable insights into underlying molecular mechanisms. Conclusions: This report extends the clinical spectrum of NUAK2-related anomalies by demonstrating a novel genotype–phenotype correlation. Our findings suggest that variants in this gene may follow a semi-dominant inheritance pattern, with heterozygous carriers manifesting milder phenotypes, such as sacral dimples, while biallelic pathogenic variants lead to severe NTDs. This observation reinforces the association between NUAK2 loss-of-function variants and NTDs and emphasizes the importance of genetic investigations in families where such dysmorphic traits recur. Ultimately, these results contribute to clarifying the molecular basis of NTDs and may inform both genetic counseling and risk stratification in affected families.


  • Open Access

    Repurposing of FDA-approved drugs as potential DNA Gyrase Inhibitors

    by Vaishali Ahlawat, Kiran Sura, Soaib Khan, Ritu Jakhar, Mehak Dangi

    Traditional drugs fail to treat bacterial infections due to the increasing development of resistance in bacteria toward the available antibiotics. Due to the high development costs and time-consuming process of new drug discovery, reprofiling of old drugs is seeking more attention with potentially lower risk of failure when taken to clinical trials. In this research article, we screened the 2588 FDA-approved drugs retrieved from Drug Bank using the in-house built NN-QSAR model and pharmacophore model. Both models were trained on the analogs of Ciprofloxacin (inhibitor of DNA Gyrase) and are known to exhibit high sensitivity and specificity. The 185 drugs screened from both models were docked against E. coli DNA gyrase, a known fluoroquinolone target. Finally, 30 drugs were screened from this 3-step approach exhibiting higher affinity towards DNA gyrase than Ciprofloxacin (standard drug). Further manual analysis of these 30 drugs made us reject certain drugs to be selected for repurposing as those are either just contrasting agents with severe side effects or are already known to possess antibacterial activity. Hence, through this study, we suggest 9 FDA-approved drugs that are either used for treating viral diseases, hypertension, or conditions like Alzheimer’s and Benign prostatic hyperplasia as potential DNA gyrase inhibitors.


  • Open Access

    Bioinformatics Approaches in the Development of Antifungal Therapeutics and Vaccines

    by Vaishali Ahlawat, Kiran Sura, Bharat Singh, Mehak Dangi, Anil Kumar Chhillar

    : Fungal infections are considered a great threat to human life and are associated with high mortality and morbidity, especially in immunocompromised individuals. Fungal pathogens employ various defense mechanisms to evade the host immune system, which causes severe infections. The available repertoire of drugs for the treatment of fungal infections includes azoles, allylamines, polyenes, echinocandins, and antimetabolites. However, the development of multidrug and pandrug resistance to available antimycotic drugs increases the need to develop better treatment approaches. In this new era of -omics, bioinformatics has expanded options for treating fungal infections. This review emphasizes how bioinformatics complements the emerging strategies, including advancements in drug delivery systems, combination therapies, drug repurposing, epitope- based vaccine design, RNA-based therapeutics, and the role of gut-microbiome interactions to combat anti-fungal resistance. In particular, we focused on computational methods that can be useful to obtain potent hits, and that too in a short period.


  • Open Access

    Epitope-based Vaccine development: A detailed overview from in-silico vaccine design to wet lab validation

    by Vaishali Ahlawat, Mehak Dangi, Anil Kumar Chhillar

    In-silico epitope-based vaccine is the cornerstone of modern vaccine development and is illuminating by a growing number of experimental and computational methods. The reverse vaccinology approach uses computational screening of the whole proteome of a pathogen to identify the proteins with the attributes of potential vaccine targets. The selection of the right components [antigenic determinants, linkers, and intramolecular adjuvants] results in the development of a multi-epitope vaccine construct with maximum efficacy and minimum adverse effects. We provide insight into the recent advancement in epitope-based vaccines and the procedure to design the modern or next-generation vaccine. The synergy between the computational screening of vaccine candidates and experimental verification to assess the immunogenic potential improves decision-making and reduces the cost and time of the development of new therapeutics


  • Open Access

    Exploring structural antigens of yellow fever virus to design multi-epitope subunit vaccine candidate by utilizing an immuno-informatics approach

    by Kiran Sura, Himanshi Rohilla, Dev Kumar, Ritu Jakhar, Vaishali Ahlawat, Deepshikha Kaushik, Mehak Dangi, Anil Kumar Chhillar


  • In silico and in vitro evaluation of designed fluconazole analogues as lanosterol 14α-demethylase inhibitors

    by Alka Khichi, Ritu Jakhar, Sweety Dahiya, Jasmine Arya, Mehak Dangi, Anil Kumar Chhillar

    The drugs fighting against aggressive fungal infections are in limited number, therefore, extensive research is obligatory to develop new therapeutic strategies. Fluconazole (FLZ) is a clinically approved drug, but resistant drug against most fungal pathogens, thus it is vital to identify more compounds that can better check the fungal growth. Analogue-based drug designing is a quick and economical way since it has inherent drug-like properties of marketed drugs. This study aims to generate and evaluate analogues of FLZ with better potency against fungal-borne infections. A total of 3307 analogues of FLZ were developed from six scaffold structures. Only 390 compounds passed Lipinski's rule, of which 247 analogues exhibited lower docking scores than FLZ with 5FSA. These inhibitors were further subjected to pharmacokinetics property evaluation and cytotoxicity test and it was found that only 46 analogues were suitable for further evaluation. Based on the molecular docking score of the best two analogues, 6f (-12.7 kcal/mol) and 8f (-12.8 kcal/mol) were selected for molecular dynamics and in-vitro studies. Antifungal activities of both compounds against 4 strains of Candida albicans were evaluated by disc diffusion assay and micro broth dilution assay and Minimum inhibitory concentrations (MICs) for 6f and 8f were observed as 256 mu g/ml against 4719, 4918 and 5480 strains but the MIC was extended to 512 mu g/ml for strain 3719. Both analogues exhibited low antifungal activities as compared to FLZ (8-16 mu g/ml). The interaction of 6f with Mycostatin was also performed using a chequerboard assay that was found additive.Communicated by Ramaswamy H. Sarma


  • Open Access

    Comparative genome analysis of Streptococcus strains to identify virulent genes causing neonatal meningitis

    by Jasmine Arya, Divya Sharma, Dev Kumar, Ritu Jakhar, Alka Khichi, Mehak Dangi, Anil Kumar Chhillar